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creativecommons.org/licenses/by-nc-nd/Abstract Aim: Obese women tend to participate less in breast cancer screening than normal
weight women. However, obese women have fattier breast than normal weight women, and
screening mammography works better in fatty than in dense breasts. One might, therefore, hy-
pothesise that obese women would actually benefit more from screening than other women.
Methods: We combined data from the Danish Diet, Cancer and Health study and the orga-
nised population-based screening mammography programme in Copenhagen, Denmark.
Women were categorised according to body mass index (BMI) (<20; 20 to <25; 25 to <30;
30 to <35, and 35þ). We measured recall rate, sensitivity and specificity for subsequent screens
with a 2-year follow-up period.
Results: The study included 6787 women. The recall rate varied from 1.4% for women with
BMI <20 to 1.9% for women with BMI 35þ, test for trend p Z 0.86. Sensitivity varied from
42% (95% confidence interval [CI] 20e64%) for women with BMI <20 to 100% (95% CI 69
e100%) for women with BMI 35þ, test for trend p Z 0.015. Specificity was fairly constant
across BMI levels, being on average 98.8%, test for trend p Z 0.79.
Conclusion: This study showed that obese women were the ones with the highest sensitivity of
screening mammography, while the specificity of screening remained stable across weight
groups. Screening programmes should be organized to encourage these women to overcome
obstacles for participation.
ª 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).f Public Health, University of Copenhagen, Østre Farimagsgade 5, DK 1014 Copenhagen K, Denmark.
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The incidence of breast cancer in post-menopausal
women is increasing in most European countries [1], and
after menopause, women with a high body mass index
(BMI) have a higher risk of breast cancer than women
with a normal BMI [2e4]. Despite their higher risk of
breast cancer, women with a high BMI tend to partici-
pate less in screening mammography than normal
weight women [5]. This has in particular been found for
women with a BMI 35þ; a group that constituted 10%
of women in a study from the US Breast Cancer Sur-
veillance Consortium [6] and 5% of women in a Danish
study [7]. However, it is easier at mammography to
detect a tumour in fatty breast tissue than in dense
breast tissue [8]. It is furthermore known that over-
weight and obese women have on average fattier breasts
than women with normal BMI [9,10].
It is, therefore, reasonable to hypothesise that over-
weight and obese women woulddprovided other factors
being equaldbenefit more from screening mammog-
raphy than normal weight women. Previous studies have
indicated somewhat conflicting results [11,12], but it
should be taken into account that these studies relied on
self-reported height and weight data.
It was the purpose of the present study to determine
sensitivity and specificity of screening mammography
based on individually linked data from a population
survey with measured height and weight and outcome
from an organised screening mammography program.
2. Materials and methods
The sensitivity is the proportion of women with breast
cancer found at screening. The specificity is the propor-
tion of women without breast cancer declared normal at
screening. If the sensitivity of screening is higher and the
specificity is not lower among overweight/obese women
than in normal weight women, then overweight/obese
women would potentially benefit more from screening
than normal weight women. The benefit of screening
might also be influenced by breast cancer incidence,
tumour type, screening lead time and available treatment;
all factors not investigated in the present study.
The Danish Diet, Cancer and Health study [13] that
forms part of the European Prospective Investigation
into Cancer and Nutrition, took place in December 1993
to May 1997. In total 79,729 women free of cancer, aged
50e64 years, and residents of greater Copenhagen or
Aarhus were invited to participate. Of these, 29,875
(37%) participated. At recruitment, height and weight
were measured by trained professionals. BMI was
calculated as (weight [kg]/[height {m}]2) and divided into
underweight and lower end of normal weight
(BMI < 20), normal weight (BMI 20 to <25), over-
weight (BMI 25 to <30), obese class I (BMI 30 to <35),
and obese classes II and III (BMI 35þ). All participantswere registered by their unique Danish personal identi-
fication number, which permitted linkage with other
data sources.
In the Copenhagen municipality, an organised,
population-based screening mammography program
started in April 1991. Women aged 50e69 years were
personally invited for screening every second year.
Screening took place in a specialised clinic. At first
screen, all women had two projections. At subsequent
screens up until 2004, women with fatty breast tissue
had one projection, while women with mixed/dense
breast tissue had two. From 2004 and onwards, all
women had two projections. Independent, double
reading was performed, and where available, mammo-
grams from up to three previous rounds were used for
comparison, and disagreements were resolved by senior
radiologists [14]. We distinguished between initial
screens representing the first screen in the program for a
given women and subsequent screens. A comprehensive
survey of all mammography activity in Denmark in 2000
showed use of opportunistic screening to be very limited
[15], thus indicating that for by far the majority of
women the first screen in the program was in fact the
first screen ever. By far the majority of screens included
in the present study was film based. Breast density data
were available from only the early part of our study
period and were not included in our analysis.
Women with screening mammograms classified as
positive were referred for assessment, and women with
screening mammography classified as negative were
invited again in 2 years. If breast cancer and/or ductal
carcinoma in situ (DCIS) were diagnosed at assessment,
the woman was counted as a screen-detected cancer or a
true positive. Otherwise, she was classified as having a
false-positive screen. Women with negative screens were
referred back to the screening program. An interval
cancer was defined as breast cancer/DCIS within the
next 2 years of a negative or a false-positive screen,
excluding the very few cases detected at the next screen,
if this took place less than 2 years since last screen.
Our study population included women who partici-
pated in the Danish Cancer and Health study and had at
least one screen in the Copenhagen organised screening
program after the date of their enrolment in the Danish
Cancer and Health study. They were followed up for
screening participation and screen-detected breast can-
cer/DCIS until 12 July 2012 and for interval cancers
until 2 years later. Incident breast cancer/DCIS cases
were identified by linkage to the Danish Cancer Register
[16] and for DCIS to data from the Danish Breast
Cancer Cooperative Group [17].
We checked for similarity across BMI groups in the
distribution of number of screens by age. Screen detec-
tion rate was defined as the number of screen-detected
cases divided by the number of screens. Recall rate was
defined as the number of positive screens divided by the
number of screens. Sensitivity was calculated as the
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detected and interval breast cancer/DCIS (true positive/
[true positive þ false negative]). Specificity was calcu-
lated as the proportion of women with a true negative
screen out of all women not diagnosed with screen-
detected or interval breast cancer/DCIS (true negative/
[true negative þ false positive]); 95% confidence in-
tervals for sensitivity and specificity were calculated as
exact binomial confidence intervals. We have calculated
the sensitivity and specificity over a 2-year period
because this is the reality for women offered screening in
Denmark.
We tested for trend in recall rate, sensitivity and
specificity across BMI groups using a binomial model
including also age group and screening round, and
taking into account that screens from a given woman are
correlated. Calculation without taking this correlation
into account did not change the results.
Data were processed using SAS (version 9.4). Ac-
cording to Danish legislation approval from the Danish
Data Inspection Agency serves as ethical approval of
register-based research with no contact to the patients,Fig. 1. Women invited to the Danish Diet, Cancer and Health (
mammography program in Copenhagen, Denmark 1993e2012.their relatives and/or their treating physician. Our
project has notification number 2008-41-2191.
3. Results
In total, 6787 women had at least one screen after their
enrolment in the Danish Diet, Cancer and Health study
(Fig. 1). Of these, 206 had only an initial screen, 5040
had only subsequent screens, and 1541 had both an
initial and subsequent screens.
Our data set included 1740 initial screens in which
only 8 screen-detected cancers and 3 interval cancers
occurred, and therefore, we did not analyse initial
screens by BMI. In total, 31,196 subsequent screens
were included. The distribution by age at screen was
fairly similar across BMI group with the average age
being 62.4 years for women with BMI 25 and 62.0
years for women with BMI <25 (Table 1).
At subsequent screens, the recall rate was 1.4% for
underweight (BMI < 20) women; 1.8% for normal
weight (BMI 20 to <25) and overweight (BMI 25 to
<30) women; 1.7% for obese class I (BMI 30 to <35);DCH) study in 1993e1997 and participating in the screening
Table 1
Number of subsequent screens by age at screen and BMI in the combined Danish Diet, Cancer and Health study and in the Copenhagen screening
mammography program 1993e2012.
Age, years BMI <20 BMI 20 to <25 BMI 25 to <30 BMI 30 to <35 BMI 35þ Total
50e54 132 (7%) 837 (6%) 567 (5%) 201 (5%) 83 (6%) 1820
55e50 481 (26%) 3457 (26%) 2489 (23%) 865 (23%) 322 (23%) 7614
60e64 590 (32%) 4502 (33%) 3620 (34%) 1281 (34%) 464 (33%) 10,457
65e69 587 (32%) 4454 (33%) 3694 (35%) 1318 (35%) 474 (34%) 10,527
70e74 39 (2.1%) 285 (2.1%) 297 (2.8%) 111 (2.9%) 46 (3.3%) 778
Total 1829 (100%) 13,535 (100%) 10,667 (100%) 3776 (100%) 1389 (100%) 31,196 (100%)
Average age (years) 61.8 62.0 62.4 62.4 62.4 62.2
Number of screens per woman 4.1 4.2 4.2 3.9 4.1 4.2
BMI, body mass index.
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(Table 2). Test for trend, pZ 0.86. In total, 183 cancers
were detected at subsequent screens, and 99 interval
cancers were observed (Table 2). There was no trend in
the crude overall breast cancer risk (screen
detected þ interval cancers) by BMI, p Z 0.90. The
sensitivity of subsequent screens increased with
increasing BMI. In underweight women, the sensitivity
was 42% (95% CI 20e64%); in normal weight women, it
was 62% (95% CI 53e71%); in overweight women, 65%
(95% CI 56e75%); in obese class I women 76% (95% CI
62e91%); and in obese classes II and III women 100%
(95% CI 69e100%). Taking age and screening round
into account, this represented a statistically significantly
increasing trend, p Z 0.015. The specificity of subse-
quent screens remained stable with increasing BMI as
the point estimates for the specificity varied only from
98.8% to 99.1%, test for trend, p Z 0.79.
4. Discussion
4.1. Main finding
This study based on combined, personal measurement
data from a population survey and an organised
screening program showed increasing sensitivity of
screening mammography with increasing BMI from a
level of 42% (95% CI 20e64%) in underweight women
to a level of 100% (95% CI 69e100%) in severely obese
women. The specificity of screening remained stable
across weight groups.
4.2. Other studies
In the present study, with 2 years of follow-up of sub-
sequent screens, the overall recall rate was 1.7%, and the
sensitivity over 2 years was 65%. In order to compare
with other studies, it is useful to know also the recall rate
for initial screens and the sensitivity over one year in the
Copenhagen program. For all screened women in
Copenhagen during the same period, the recall rates
were 4.4% and 1.8% for initial and subsequent screens,
respectively. With a 1-year follow-up, the sensitivity was90% and 89% for initial and subsequent screens,
respectively [18] (Table 3).
Based on the Million Women Study from the United
Kingdom (UK) and including both initial and subse-
quent screens, Banks et al. [11] found the recall rate for
women with a BMI <25 to be 3.9% and for women with
a BMI 25 to be 3.5%. With a 1-year follow-up, the
sensitivity was 85.7% (95% CI 81.2e89.3) and 91.0 (95%
CI 87.5e93.6), respectively, and the specificity was
97.2% (95% CI 97.0e97.3) and 97.4% (95% CI
97.3e97.6), respectively (Table 3). These estimated were
adjusted for age, likelihood of previous National Health
Service breast screening, screening center, pervious
breast surgery, menopausal status, and use of hormone
therapy. Although the UK recall rates were higher for
normal weight than for overweight þ women, the
sensitivity and specificity patterns were as see in
Copenhagen.
Our data were only in part in agreement with those of
Elmore et al. [12]. They analysed data from the Group
Health Cooperative in the Northwestern United States
and included both initial and subsequent screens. In this
study, the crude recall rate was fairly similar across BMI
groups varying between 11.5% and 12.3%. The crude
sensitivity increased from 84.6% (95% CI 79.8e88.6) for
underweight and normal weight women to 91.3% (95%
CI 82.8e96.4) for obesity classes IIeIII women, though
with overlapping confidence intervals. The crude speci-
ficity was fairly similar across BMI groups varying be-
tween 88.3% and 89.0% (Table 3).
The US estimates [12] changed when they were
adjusted for age, breast density, menopausal and hor-
mone therapy status, breast symptoms, family history of
breast cancer, history of breast biopsy, and time since
last mammogram. The adjusted odds ratio of recall was
1.31 (95% CI 1.22e1.41) for obesity classes IIeIII
women compared to that of underweight and normal
weight women. The adjusted odds ratio for sensitivity
was 0.89 (95% CI 0.52e1.55) for overweight, 0.88 (95%
CI 0.44e1.82) for obesity class I, and 1.13 (95% CI
0.47e3.02) for obesity classes IIeIII women compared
to that of underweight and normal weight women. The
adjusted odds ratios for specificity were 0.86 (95% CI
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0.71e0.82), respectively. The authors concluded that
‘obese women had a more than 20% increased risk of
having a false-positive mammogram result compared
with underweight and normal weight women’, and the
authors found the ‘finding that obese women have less
accurate mammograms . surprising’. These conclu-
sions from the authors will be discussed below.
With a purpose somewhat different from ours, Ker-
likowske et al. [7] examined whether extent of
mammography use and accuracy of mammography
modified the association between BMI and rate of breast
cancer. They included only post-menopausal women not
currently using hormone therapy and found that the
odds ratio of breast cancer, controlled for a number of
potential confounders, increased with increasing BMI.
The purpose of our study was exclusively to assess the
association between BMI and screening sensitivity. Our
study population was more heterogeneous (including
both pre- and post-menopausal women and both users
and non-users of hormone therapy) than at the one
studied by Kerlikowske et al., and we found no trend in
breast cancer risk by BMI. Anyhow, Kerlikowske et al.
also found a higher sensitivity for women with a BMI
25 (89.0%; 95% CI 85.9e91.2), than for women with a
BMI <25 (84.0%; 95% CI 79.3e87.6; Table 3).
An Australian study found slightly improved sensi-
tivity of screening mammography in women aged 50e69
years with larger sized breasts, 94.51%, compared to
women with average sized breasts (91.13% [19], Table 3).
4.3. Strength and weakness
It was a strength of our study that all data derived from
objective measurements thus avoiding any recall bias. It
was furthermore a strength that the study population
had very limited use of opportunistic screening. Is was a
weakness of our study that we could only include
women participating in the Danish Diet, Cancer and
Health study, as these women health wise constituted a
somewhat selected group with an overall mortality
below that of the general population [20]. Participants
in the Diet, Cancer and Health cohort were on average
healthier than non-participants. The overall mortality
rate ratio for non-participants compared with partici-
pants was 2.29 (95% CI 2.19e2.40) compared with
participants. Anyhow, this selection affected all women
in our study as we relayed only on internal
comparisons.
The overall 2-year sensitivity in our study was 65%,
which was slightly lower than the 71% for the Copen-
hagen program overall (unpublished data). The differ-
ence might be due to the fact that participants in the
Diet, Cancer and Health cohort were healthier than the
average of Copenhagen women, and the proportion of
obese women was, therefore, expected to be lower in our
cohort than in the Copenhagen population at large.
Table 3
Overview of sensitivity and specificity, including 95% confidence intervals, of screening mammography by BMI.
Study Screen type Follow-up time BMI Total
BMI <20 BMI 20 to <25 BMI 25 to <30 BMI 30 to <35 BMI 35þ
Sensitivity
Present study S 2 years
since last
2 Years 42% (20e64) 62% (53e71) 65% (56e75) 76% (62e91) 100% (69e100) 65%
(59e100)
Kemp Jacobsen
et al, 2015 [18]
1 Year NA NA NA NA NA 88.9%
(86.5e90.9)
Banks et al, 2004 [11] I þ S 1 Year 83.8% Crude
85.7% Adja
(81.2e89.3)
89.8% Crude
91.0% Adja
(87.5e93.6)
86.6% Crude
NA
Elmore et al, 2004 [12] I þ S 1 Year 84.6% Crude
(79.8e88.6)
OR 1 (baseline)
85.9% Crude
(80.7e90.2)
OR 0.89 Adjb
(0.52e1.55)
86.2% Crude
(78.6e91.9)
OR 0.88 Adjb
(0.44e1.82)
91.3% Crude
(82.8e96.4)
OR 1.13 Adjb
(0.47e3.02)
86.0% Crude
(83.3e88.5)
NR
Kerlikowske
et al, 2008 [7]
S 1 year
since last
1 Year 79.9% (76.3e82.7) Adjc 86.1% (83.5e88.1) Adjc NA
Kerlikowske
et al, 2008 [7]
S 2 years
since last
1 Year 84.0% (79.3e87.6) Adjc 89.0% (85.9e91.2) Adjc NA
Gayde et al, 2012 [19] I þ S 1 year Average size breasts, 50e59 years: 86.77%d Larger size breasts, 50e59 years: 94.01%d NA
Gayde et al, 2012 [19] I þ S 1 Year Average size breasts, 60e69 years: 91.13%e Larger size breasts, 60e69 years: 94.51%e NA
Specificity
Present study S 2 years
since last
2 Years 99.1% (98.6e99.5) 98.8% (98.6e99.0) 98.8% (98.6e99.0) 99.0%
(98.7e99.3)
98.8%
(98.3e99.4)
98.8%
(98.7e99.0)
Kemp Jacobsen
et al, 2015 [18]
1 Year NA NA NA NA NA 98.8%
(98.8e98.9)
Banks et al, 2004 [11] 1 þ 2 1 year 96.6% Crude
97.2% Adja
(97.0e97.3)
97.0% Crude
97.4% Adja
(97.3e97.6)
96.8% Crude
NA
Elmore et al, 2004 [12] I þ S 1 Year 89.0% Crude
(88.7e89.3)
OR 1 (baseline)
88.3% Crude
(88.0e88.7)
OR 0.86
Adjb (0.81e0.90)
88.3% Crude
(87.8e88.8)
OR 0.79
Adjb (0.74e0.84)
88.5% Crude
(87.9e89.0)
OR 0.77
Adjb (0.71e0.82)
88.6% Crude
(88.4e88.8)
NR
Kerlikowske
et al, 2008 [7]
S 1 year
since last
1 Year Non-screen detected per 1000 examinations: 0.8 (0.7e1.0) Non-screen detected per 1000 examinations: 0.6 (0.6e0.8) NA
Kerlikowske
et al, 2008 [7]
S 2 years
since last
1 Year Non-screen detected per 1000 examinations: 0.8 (0.6e1.1) Non-screen detected per 1000 examinations: 0.7 (0.6e0.9) NA
Gayde et al, 2012 [19] I þ S 1 Year Average size breasts, 50e59 yearsd: 95.54%e Larger size breasts, 50e59 yearsd: 96.41%e NA
Gayde et al, 2012 [19] I þ S 1 Year Average size breasts, 60e69 yearsd: 96.91%e Larger size breasts, 60e69 yearsd: 97.35%e NA
BMI, body mass index; NA, not available; NR, not relevant; OR, odds ratio; I, initial; S, subsequent.
a Adjusted for age, likelihood of previous NHS breast screening programme screening, screening center, previous breast surgery, menopausal
status, and use of hormone replacement therapy.
b Adjusted for age, breast density, menopausal or hormone therapy status, breast symptoms, family history of breast cancer, history of breast
biopsy or surgery, and time since last mammogram.
c Adjusted for age, race, and mammography registry.
d Categorized only according to breast size and not according to BMI.
e Difference not statistically significant at the 0.05 level.
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lowed for only a short time period after the women
stopped to be invited to screening. Due to the lead time
bias, it would, therefore, not make sense to compare the
breast cancer incidence between screened and non-
screened obese women. It is a weakness in the study
that BMI was measured only at time of recruitment.
However, the largest possible age span between
recruitment and screening was from age 50 to age 67
years, a period in life with limited changes in female
BMI [21].
Although the Diet, Cancer and Health study had
information on a number of breast cancer risk factors,
we did not include these factors in the analysis. The
reason being that the purpose of our study was to
determine the sensitivity and specificity of screening
mammography for obese women. All women know the
size and shape of their body, while few women know
their breast cancer risk factors. It was not the purpose of
our study to clarify whether BMI was a determinant of
sensitivity and specificity independently of other breast
cancer risk factors.
4.4. Clinical implications
Although the European data from the UK and
Denmark at surface seem to differ from the data from
the Northwestern United States, this might derive from
differences in the analysis. In the study from the Group
Health Cooperative, breast density was included in the
list of variable adjusted for in the analysis [12]. How-
ever, BMI and breast density correlated in this as in
other studies as overweight and obese women had more
fatty breasts than normal weight women [9,10,12].
Adjustment for breast density in the measurement of the
association between obesity and mammography sensi-
tivity will, therefore, tend to eliminate any sensitivity
advantage that obese women might have in screening.
Furthermore, the crude US data showed no difference in
specificity across BMI groups. The ‘20% increased risk
of having a false-positive mammogram result’ [12]
appeared only after adjustment in the analysis for
breast density and other variables. Overall, the available
data, therefore, show the unadjusted sensitivity of
screening mammography to be higher in obese than in
normal weight women, while the unadjusted specificity
remains fairly constant over weight groups of women.
In the United States, 24 states have now implemented
breast density notification laws requiring physicians to
notify women who have undergone mammography and
were found to have dense breast tissue [22]. Although
this information will allow women to include the density
information in their decision on screening participation,
density information is not available for all women and
not for potential first-time users. In contrast, all women
know the shape of their body. In terms of the public
health advice to be derived from these screening studies,it is, therefore, more relevant for obese women to be
informed about the crude than the adjusted screening
sensitivity and specificity. Unadjusted, both data from
the UK, the United States, and from Denmark indicated
a higher sensitivity and a constant specificity for obese
women compared with that of normal weight women.
It is, therefore, important to encourage obese women
to overcome obstacles and to participate in screening.
There are two ways in which this message can be
conveyed. First, information material in text should
include the positive message to obese women about their
expected benefit from screening. Second, photos illus-
trating screening should include imagesdor dra-
wingsdof obese women stressing that this is also a
preventive measure available for them and not only for
the normal weight women most often shown in infor-
mation material.
In conclusion, based on linkage of objective height
and weight measures with the outcome from an organ-
ised population-based screening program, we found the
sensitivity of mammography to increase with increasing
BMI and the specificity to remain constant across BMI
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